Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336107 | 0.88 | CA1 (0.54) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL28335829 | 0.88 | CA1 (0.59) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL383516 | 0.88 | CA1 (0.54) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL1154451 | 0.84 | TSHR (0.59) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL2478971 | 0.83 | TSHR (0.56) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL30061803 | 0.83 | TSHR (0.56) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL8709902 | 0.82 | CA1 (0.53) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL3337006 | 0.82 | CA1 (0.53) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL7171606 | 0.82 | CA1 (0.53) | CA1CA2ALDH1A1TSHRCASP1 | |
| SCHEMBL17262953 | 0.82 | CA1 (0.53) | CA1CA2ALDH1A1TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612134-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095005-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20180244600-A1 | Purification of 3,6-dichlorosalicylic acid using selective solubilization of impurities | FRAMROZE BOMI P (US) | 2018-08-30 | — | — | US | disclosed |
| US-20140374733-A1 | PHOTOELECTRIC CONVERSION ELEMENT, METHOD FOR USING THE SAME, IMAGING DEVICE, PHOTOSENSOR, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140374733-A1 | PHOTOELECTRIC CONVERSION ELEMENT, METHOD FOR USING THE SAME, IMAGING DEVICE, PHOTOSENSOR, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| EP-1651640-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005009994-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-4935511-A | Nervous system, gastrointestinal disorders | RORER PHARMACEUTICAL CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | CA1 3884/4885CA2 2101/4885ALDH1A1 356/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | CA1 3224/4885CA2 2352/4885ALDH1A1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.